MedTrace Logo

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

NCT01483599 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 293

Last updated 2017-08-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of CNTO 1959 in the treatment of patients with moderate to severe plaque psoriasis.

Conditions

Interventions

DRUG

CNTO 1959 (5 mg)

Subcutaneous (SC) injections

DRUG

CNTO 1959 (15 mg)

SC injections

DRUG

CNTO 1959 (50 mg)

SC injections

DRUG

CNTO 1959 (100 mg)

SC injections

DRUG

CNTO 1959 (200 mg)

SC injections

DRUG

Adalimumab

SC injections

DRUG

Placebo

SC injections

Sponsors & Collaborators

  • Janssen Inc.

    lead INDUSTRY

Principal Investigators

  • Janssen Inc. Clinical Trial · Janssen Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-10
Primary Completion
2012-11-27
Completion
2013-08-05

Countries

  • United States
  • Belgium
  • Canada
  • Germany
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01483599 on ClinicalTrials.gov